Integration of pro- and anti-angiogenic signals by endothelial cells

被引:0
|
作者
Shideh Kazerounian
Jack Lawler
机构
[1] Boston Children’s Hospital and Harvard Medical School,The Department of Pediatrics, Division of Genetics and Genomics
[2] Beth Israel Deaconess Medical Center and Harvard Medical School,The Department of Pathology
关键词
thrombospondin-1; TSP-1; vascular endothelial growth factor; VEGF; dormancy; angiogenesis; cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Angiogenesis or neovascularization is a complex multi-step physiological process that occurs throughout life both in normal tissues and in disease. It is tightly regulated by the balance between pro-angiogenic and anti-angiogenic factors. The angiogenic switch has been identified as the key step during tumor progression in which the balance between pro-angiogenic and anti-angiogenic factors leans toward pro-angiogenic stimuli promoting the progression of tumors from dormancy to dysplasia and ultimately malignancy. This event can be described as either the outcome of a genetic event occurring in cancer cells themselves, or the positive and negative cross-talk between tumor-associated endothelial cells and other cellular components of the tumor microenvironment. In recent years, the mechanisms underlying the angiogenic switch have been extensively investigated in particular to identify therapeutic targets that can lead to development of effective therapies. In this review, we will discuss the current findings on the regulatory pathways in endothelial cells that are involved in the angiogenic switch with an emphasis on the role of anti-angiogenic protein, thrombospondin-1 (TSP-1) and pro-angiogenic factor, vascular endothelial growth factor (VEGF).
引用
收藏
页码:171 / 179
页数:8
相关论文
共 50 条
  • [1] Integration of pro- and anti-angiogenic signals by endothelial cells
    Kazerounian, Shideh
    Lawler, Jack
    [J]. JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2018, 12 (01) : 171 - 179
  • [2] Pro- and anti-angiogenic agents
    Bridoux, A.
    Mousa, S. A.
    Samama, M-M
    [J]. JOURNAL DES MALADIES VASCULAIRES, 2012, 37 (03) : 132 - 139
  • [3] Polymers for pro- and anti-angiogenic therapy
    Fischbach, Claudia
    Mooney, David J.
    [J]. BIOMATERIALS, 2007, 28 (12) : 2069 - 2076
  • [4] Pro- to Anti-angiogenic Ratio in Preeclampsia
    Kharb, Simmi
    Tiwari, Radha
    Nanda, Smiti
    [J]. CURRENT WOMENS HEALTH REVIEWS, 2019, 15 (02) : 137 - 142
  • [5] Pro- and Anti-Angiogenic Actions of Metformin
    Triggle, Chris
    Samuel, Samson M.
    Lakshmanan, Arun
    Ghosh, Suparna
    Majeed, Yasser
    Upadhyay, Rohit
    Gnanapragasam, Arunachalam
    Ding, Hong
    [J]. JOURNAL OF VASCULAR RESEARCH, 2016, 53 : 44 - 44
  • [6] Identification of pro- and anti-angiogenic MicroRNAs
    Kuehlbacher, Angelka
    Urbich, Carmen
    Zeiher, Andreas M.
    Dimmeler, Stefanie
    [J]. CIRCULATION, 2007, 116 (16) : 175 - 175
  • [7] Differential effects of pravastatin on secretion of pro- and anti-angiogenic factors from trophoblast and endothelial cells
    Gillham, Haley Elizabeth
    Banek, Christopher Todd
    Needham, Karen
    Gilbert, Jeffrey
    [J]. FASEB JOURNAL, 2013, 27
  • [8] Matrix metalloproteinases: Pro- and anti-angiogenic activities
    Raza, SL
    Cornelius, LA
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2000, 5 (01) : 47 - 54
  • [9] Expression profiles of pro- and anti-angiogenic factors in human granulosa cells
    Keck, C.
    Pietrowski, D.
    [J]. HUMAN REPRODUCTION, 2001, 16 : 209 - 210
  • [10] Pro- and anti-angiogenic therapy and atherosclerosis with special emphasis on vascular endothelial growth factors
    Vuorio, Taina
    Jauhiainen, Suvi
    Yla-Herttuala, Seppo
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (01) : 79 - 92